Quality of life data are still being analyzed, according to Dr. Dalgleish. “But ... from my personal experience, the patients do feel better on the vaccine as [it has] a kind of overall boosting effect.”
The investigators plan to take IMM-101 forward in clinical trials, he said. “But I think in the States, they might want to do that with Abraxane first line.” In the United Kingdom, the National Institute for Health and Care Excellence (NICE) recently declined Abraxane, meaning cost won’t be reimbursed if it is used, Dr. Dalgleish said. “So we may well be able to do the same study in Europe in order to get approval, although personally, I’d be very keen for conditional approval on this [trial] in the U.K. because it has a clear benefit without any toxicity. And there is a system where you can get a phase 4 approval and have postapproval monitoring.”
Dr. Dalgleish disclosed that he has a consulting or advisory role with and receives research funding from Immodulon Therapeutics.
